SCHEMBL4588005

SCHEMBL4588005

CC(C)(S)CNCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAOA P21397 1/20 0.47
MAPT P10636 2/20 0.45
CHRM2 P08172 1/20 0.45
GAA P10253 1/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
SIGMAR1 Q99720 1/20 0.42
ADH1B P00325 1/20 0.42
ADH1C P00326 1/20 0.42
ADH1A P07327 1/20 0.42
ADH7 P40394 1/20 0.42
THRB P10828 2/20 0.42
TP53 P04637 1/20 0.42
IDO1 P14902 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461543 0.83 MEN1 (0.56) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL6428779 0.80 ESR1 (0.45) MEN1KMT2AMAPTGAAKDM4E
SCHEMBL3926325 0.79 SLC6A2 (0.54) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL15114181 0.79 MEN1 (0.58) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL2013167 0.79 MEN1 (0.57) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL23474625 0.78 MEN1 (0.50) MEN1KMT2ATDP1MAOAMAPT
Ammonia Solution, Strong SCHEMBL15636013 0.78 MEN1 (0.50) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL5675110 0.78 MEN1 (0.50) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL15636012 0.76 MEN1 (0.48) MEN1KMT2ATDP1MAOAMAPT
SCHEMBL9936240 0.76 KMT2A (0.50) MEN1KMT2ATDP1MAOAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332505-B2 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-02-19 US disclosed
US-20060009431-A1 Nitrosated and nitrosylated compounds, compositions and methods use NITROMED, INC. (US) 2006-01-12 US disclosed
EP-1603933-A2 NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-12-14 EP disclosed
EP-1154771-A4 NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-04-20 EP disclosed
US-6852739-B1 Methods using proton pump inhibitors and nitric oxide donors NITROMED INC. (US) 2005-02-08 US disclosed
US-20040266828-A1 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use NITROMED, INC. (US) 2004-12-30 US disclosed
WO-2004098538-A2 NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-11-18 WO disclosed
EP-1154771-A1 NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-11-21 EP disclosed
WO-2000050037-A1 NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009431-A1 Nitrosated and nitrosylated compounds, compositions and methods use TBXA2R, TXNRD3, NOS3 MEN1 4145/4885KMT2A 3639/4885TDP1 2093/4885
US-20040266828-A1 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use NOS2, NOS1, PTGS2 MEN1 2357/4885KMT2A 2820/4885TDP1 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.